Rasmus Pihl

Rasmus Pihl

Auto-generated profile, based on publicly available information

Rasmus Pihl

Department of Biomedicine, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
RPRasmus Pihl
Rasmus Pihl
Qingfei ZhengQingfei Zheng
Qingfei Zheng
YDYael David
Yael David
1

8 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
RPRasmus Pihl
Rasmus Pihl
RJRasmus K. Jensen
Rasmus K. Jensen
EPEmil C. Poulsen
Emil C. Poulsen
LJLisbeth Jensen
Lisbeth Jensen
AHAnnette G. Hansen
Annette G. Hansen
STSteffen Thiel
Steffen Thiel
ITIH4 forms complexes with proteases upon cleavage that inhibit proteolysis by a novel inhibitory mechanism.

1 September 2018 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
NBNirmal K Banda
Nirmal K Banda
DDDhruv Desai
Dhruv Desai
RSRobert I Scheinman
Robert I Scheinman
RPRasmus Pihl
Rasmus Pihl
HSHideharu Sekine
Hideharu Sekine
VHV. Michael Holers
V. Michael Holers
Mannan-binding lectin–associated serine protease 3 (MASP-3) regulates the alternative pathway of complement and is predominantly synthesized in the liver. The role of liver-derived MASP-3 in the pathogenesis of rheumatoid arthritis (RA) is unknown. We hypothesized that liver-derived MASP-3 is essential for the development of joint damage and that targeted inhibition of MASP-3 in the liver can attenuate arthritis. We used MASP-3–specific small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine (GalNAc) to specifically target the liver via asialoglycoprotein receptors. Active GalNAc–MASP3–siRNA conjugates were identified, and in vivo silencing of liver MASP-3 mRNA was demonstrated in healthy mice. The s.c. treatment with GalNAc–MASP-3–siRNAs specifically decreased the expression of MASP-3 in the liver and the level of MASP-3 protein in circulation of mice without affecting the levels of the other spliced products. In mice with collagen Ab–induced arthritis, s.c. administration of GalNAc–MASP-3–siRNA decreased the clinical disease activity score to 50% of controls, with decrease in histopathology scores and MASP-3 deposition. To confirm the ability to perform MASP-3 gene silencing in human cells, we generated a lentivirus expressing a short hairpin RNA specific for human MASP-3 mRNA. This procedure not only eliminated the short-term (at day 15) expression of MASP-3 in HepG2 and T98G cell lines but also diminished the long-term (at day 60) synthesis of MASP-3 protein in T98G cells. Our study demonstrates that isoform-specific silencing of MASP-3 in vivo modifies disease activity in a mouse model of RA and suggests that liver-directed MASP3 silencing may be a therapeutic approach in human RA.

11 March 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
TLTea Lund Laursen
Tea Lund Laursen
LBLars Bossen
Lars Bossen
RPRasmus Pihl
Rasmus Pihl
ATAnne Troldborg
Anne Troldborg
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
STSteffen Thiel
Steffen Thiel
There is an unmet need for new biomarkers to improve diagnostics and prognostics in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Inter-α-inhibitor heavy chain 4 (ITIH4) is an abundant, liver-produced protein, and its synthesis may be altered in liver diseases. We investigated whether ITIH4 plasma concentrations were affected in PBC and PSC patients.